| Jan Christopher Sitko, ATC, LPN | |
|
6000 W Touhy Ave Ste 202, Chicago, IL 60646-1248 | |
| (773) 774-4291 | |
| (773) 774-4527 |
| Full Name | Jan Christopher Sitko |
|---|---|
| Gender | Male |
| Speciality | Specialist/technologist - Athletic Trainer |
| Location | 6000 W Touhy Ave Ste 202, Chicago, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497250302 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 043.116227 (Illinois) | Secondary |
| 2255A2300X | Specialist/technologist - Athletic Trainer | 096.004640 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jan Christopher Sitko, ATC, LPN 1670 Kingsdale Rd, Hoffman Estates, IL 60169-4039 Ph: (847) 421-0746 | Jan Christopher Sitko, ATC, LPN 6000 W Touhy Ave Ste 202, Chicago, IL 60646-1248 Ph: (773) 774-4291 |
News Archive
Celgene Corporation: "The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success".
Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.
Despite an inward focus on domestic issues like healthcare and forward-looking concerns over global warming, an overwhelming number of Americans (66%) believes that the United States has an obligation to help poor children around the world.
Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.
Drivers over age 65 are the fastest-growing segment of the driving population, and their eye care providers-ophthalmologists and optometrists-are playing an increasingly important role in assessing their ability to drive safely.
› Verified 1 days ago